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Abstract
Calcium homeostasis has a pivotal role in regulating many biological processes. 
The interplay of calcium-regulating hormones, including parathyroid hormone 
(PTH), vitamin D, and calcitonin, is crucial in tightly maintaining serum calcium 
levels. Deregulation of calcium homeostasis has clinical implications resulting in 
hypercalcemia or hypocalcemia, which can lead to metabolic bone disease (MBD). 
MBD is a group of multifactorial bone diseases, caused by bone demineralization 
and characterized by an increased susceptibility to fracture risk. This chapter aims to 
provide an overview of associated risk factors and diagnostic, prevention, and recent 
treatment methods for MBD. The diagnosis of MBD is based on the assessment of 
clinical signs, radiological findings, quantitative ultrasonography, and biochemical 
evaluation of serum calcium, phosphate, PTH, alkaline phosphatase, and vitamin 
D. Current pharmacological treatments include antiresorptive and anabolic con-
ventional therapies. Additionally, the efficacy of herbal extracts and nutritional 
supplements have been evaluated. Recent advances in the MBD management include 
drugs targeting calcium-sensing receptor and parathyroid hormone-related pro-
teins, leading to the development of cathepsin K and Src tyrosine kinase inhibitors, 
calcilytics, and monoclonal antibodies against sclerostin or Dickkopf-1. Moreover, 
new nanomaterials have been used for improving the surgical treatment of vertebral 
fractures.
Keywords: calcium, parathyroid hormone, metabolic bone disease, osteoporosis, 
vitamin D, anabolic drug, antiresorptive drugs
1. Introduction
Metabolic bone disease (MBD), the third most prevalent disorder of the 
endocrine system, involves any disorder that alters the phenomena of mineral-
ization in the normal skeleton. The disorder is primarily caused by abnormalities 
in the structure of bone or its mass, vitamin D level as well as the presence of 
certain minerals such as calcium and phosphorus [1].
The concentration of extracellular calcium is crucial for several functions at the 
cellular level, which needs to be retained in restricted levels. The free concentration 
of calcium is predominantly negatively regulated by the secretion of the parathyroid 
hormone (PTH) in response to calcium-sensing receptors. A substantial drop in the 
level of free calcium activates the release and synthesis of PTH, which often leads to 
calcium reabsorption in the renal tubules, enhanced secretion of calcitriol (vitamin D3) 
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promoting calcium absorption from the intestine, and immediate release of calcium 
from the skeleton, which contains 99% of calcium in the body. Conversely, in regard 
to rising levels of calcium in the body, PTH level drops that lead to a decline in the 
above-stated processes. This balance is seen to be disturbed in various pathological 
circumstances leading to elevated or low calcium levels. High calcium levels, known as 
hypercalcemia, and low calcium levels, known as hypocalcemia, are observed in condi-
tions such as hypoparathyroidism and vitamin D deficiency.
The most common forms of MBD comprises of osteoporosis, osteomalacia, 
primary hyperparathyroidism, and fluorosis, while fibrous dysplasia, Paget’s 
disease, osteogenesis imperfecta, and tumor-induced osteomalacia account for its 
rare forms.
Osteoporosis is a severe MBD that constitutes to be a serious health issue for older 
people. It represents a decline in the bone mass per unit volume, leading to signifi-
cant weaknesses in the bone structure, which ultimately leads to bone deformity/
fracture. Osteoporosis is categorized as primary when there is no prominent diag-
nosis of the disease and secondary when an established contributing cause such as 
steroid treatment is detectable. Type I (postmenopausal) and type II (age-related) 
are categorized under primary osteoporosis. Type I osteoporosis incorporates bone 
loss with the expedited bone mass reduction due to the withdrawal of estrogens [2].
Osteomalacia results from curtailed absorption of calcium and phosphate in the 
intestine due to a deficiency in vitamin D or more rarely due to calcium or phos-
phate deficiency. Joint pain with fragility in bone and muscular weakness are the 
common symptoms observed in patients with osteomalacia [3].
Paget’s disease leads to skeletal lesions resulting in progressive bone turnover. 
The finely constructed bone lacks a natural lamellar framework and has poor quality 
with effects like bone deformity with prominent fractures and related pain [4].
Hyperparathyroidism results due to excess secretion of PTH, which can be 
categorized as primary hyperparathyroidism or secondary hyperparathyroidism. 
Primary hyperparathyroidism occurs due to the raised concentration of calcium in 
the serum. Research reports show hypercalcemia with an abnormally high level of 
alkaline phosphatase and elevated serum PTH [5].
Fibrous dysplasia is categorized as a rare form of metabolic disorder in which 
the bones are covered with irregular structures, which appear as a scar-like fibrous 
tissue. This deposited structure affects bone structure and integrity, making it more 
fragile and fracture-prone.
This chapter discusses in brief about the associated risk factors and diagnosis of 
MBD along with the preventive measures and the pharmacological approaches for 
the treatment of MBD.
2. Associated risk factors
Several contributing factors that control bone mass are diet, lifestyle, levels of 
cytokines, level of mobilization and physical activity, hormones, genetic factors, 
and local growth factors. Table 1 illustrates premature risk factors associated with 
MBD for both antenatal and postnatal period.
The amalgamation of various nutritional and biomechanical factors results in 
the precipitation of MBD. Some of them are discussed below:
2.1 Vitamin D deficiency
Vitamin D is inevitable for retaining the rate of metabolism in bone. The major 
function of vitamin D is to boost calcium and phosphorus intestinal absorption by its 
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active metabolite 1,25dihydroxyvitamin D3 along with fostering the continuance of 
neuromuscular function as well as bone remodeling. Disorders in which this active 
metabolite is deficient can pose a greater risk of the incidence of bone disorders [6]. 
Low levels of vitamin D results in decreased absorption of intestinal calcium and 
phosphorus, with a drop in the level of calcium in serum with an increased synthesis of 
PTH. A rise in the level of PTH in plasma preserves the level of normal serum calcium 
by enhancing 1,25-(OH)2D renal development, growing bone yield, and escalating loss 
in mass of bone. Lack of sufficient intake or a maternal lack of vitamin D is the most 
leading cause of deficiency of vitamin D. Renal failure or the incidences of hepatic dis-
ease, receptor defects, or synthesis of congenital vitamin D are the other instances that 
cause a vitamin D deficiency. Additionally, two other rare genetic diseases, including 
vitamin D-dependent rickets type 1 or pseudovitamin D deficiency rickets, are caused 
due to the mutation in the gene encoding 1α-hydroxylase enzyme (CYP27B1 gene), 
which is a rate-limiting enzyme involved in the bioactivation of vitamin D.
A recent report has evaluated vitamin D status and its relationship with skeletal 
health in 40 healthy adult Nigerians (aged between 21 and 50 years) [7]. An array 
of physiological parameters were evaluated, which predominantly included markers 
of bone health, thyroid function and renal function, levels of parathyroid hormone, 
calcium excretion rates, and serum 25-hydroxyvitamin-D levels. The observed 
results indicated the fact that approximately 70% of the reported cases had an 
incidence of vitamin D insufficiency with 25% of the subjects indicated osteo-
penia, while none of the subjects presented with osteoporosis. The bone mineral 
density (BMD) T-score for osteopenic subjects was significantly lower than for 
non-osteopenic subjects. It was also observed that osteocalcin levels in serum were 
considerably higher in osteopenic subjects versus non-osteopenic subjects; however, 
a 24-hour calcium excretion was comparable between the two groups. Mean serum 
25-hydroxyvitamin-D was lower in subjects with osteopenia compared to non-
osteopenic subjects, while parameters for thyroid, renal, and calcium-phosphorus 
were not significantly different in the observed group [7].
2.2 Disorders related to homeostasis of calcium and phosphorus
Disorders related to homeostasis of calcium and phosphorus results in ultimate 
clinical consequences for neonates. A fine positive balance between calcium and 
phosphorus is indispensable for sufficient bone growth and maturation. Neonates 
with persistent malabsorption are at high prospects of poor absorption of cal-
cium, phosphorus, magnesium, or vitamin D, either due to medical or surgical 
interventions [8].
2.3 Drug-related factors
Some drugs that are frequently used in premature births also support the inci-
dence of MBD. Some of the prominent classes of such drugs are loop diuretics such 
Antenatal Postnatal
Preclampsia Liver and kidney disease
Placental insufficiency Use of drugs such as loop diuretics, methylxanthines, 
glucocorticoids
Prevalence of neuromuscular disorders, 
intraventricular hemorrhage
Prevalence of bronchopulmonary dysplasia
Table 1. 
List of premature risk factors associated with metabolic bone disorders for both antenatal and postnatal period.
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as furosemides, corticosteroids, methylxanthines, antifungals, and certain antiepi-
leptics. The most probable reason may be activation of osteoclasts and reduction of 
osteoblast proliferation and decreased absorption, thereby the ultimate elimination 
of calcium by the kidneys [9].
2.4 Parent related nutrition
The concentration of minerals such as calcium and phosphorus in premature 
breast milk is inadequate in regard to the estimated requirement, presuming that 
they ingest approximately one third that is essential in fetal life [9]. In addition, 
milk products are high in concentration of the stated minerals but have a lower 
bioavailability; hence, consumption of mineral fortified milk is essential for 
preventing and treating MBD.
2.5 Biomechanical factors
Biomechanical factors that impact the alteration of bone structure is accountable 
for the reduction of bone mass caused by reduced activity level. The majority of 
bone-loading process occurs during the third trimester. Nevertheless, in the absence 
of bone loading, bone formation stops and further osteoclasts are activated leading 
to a reduction in bone strength [10]. Neonatal demineralization of the skeleton may 
result from immobilization due to the prevalence of other disease conditions or 
neurological implications.
2.6 Endocrinology-related factors
Thyroid hormones are prerequisite for the development of the skeleton and 
are prime regulators of bone maintenance. Hypothyroidism induces delayed 
development of the skeleton and growth retardation with delayed bone develop-
ment owing to inadequate endochondral ossification. Hyperparathyroidism also 
impacts bone metabolism, which causes significant conditions such as hypercalce-
mia, demineralization of the bone, and delay in growth and development. Due to 
these abovementioned-stated issues, a decline in the normal function of kidneys 
eventually leads to mineral and bone metabolism disturbances culminating in 
serious skeletal deformities [11].
3. Diagnosis
Since there are no ultimate diagnosis and therapy indications for MBD, and 
the related sign and symptoms also appear very late, it is, therefore, appropriate to 
monitor the subjects at risk for the development of the related disorder.
3.1 Serum markers
Levels of alkaline phosphatase (ALP) rise physiologically at about 6–12 weeks 
of age over the first 3 weeks of life. Regardless of the lack of signs and symptoms, 
ALP levels > 500 IU/L suggest impaired bone homeostasis and values >700 IU/L is 
associated with bone demineralisation [12].
Serum phosphate levels <5.6 mg/dl are strongly linked with the prevalence of the 
radiologically apparent disorder in preterm infants with an average gestational age 
of 24.7–33.0 weeks [13].
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3.2 Urinary markers
Hypophosphatemia is the most prevalent physiological modification coupled 
with premature MBD, which causes a reduced release of PTH and thereby increases 
the reabsorption of phosphate from the renal tubular. Infants born <28 weeks of 
gestation have a reduced baseline value for phosphate, resulting in increased excre-
tion of phosphate in urine, even in the mere existence of lower levels of phosphate 
that appear as a significant marker for MBD incidence [14].
3.3 Radiological markers
Dual-energy X-ray absorptiometry (DEXA) is the conventional method used for 
BMD assessments. DEXA employs the use of low ionizing radiation and measures 
the calcium content in bone in terms of grams of hydroxyapatite/cm2.
Quantitative ultrasound is another technique that is relatively inexpensive and 
measures the mineral content of bone as well as the organic matrix. The parameters 
that are evaluated by the abovementioned technique are the speed of sound and 
bone transmission time [15].
4. Prevention of MBD
There are certain non-pharmacological approaches that need to be inculcated in 
daily life for the prevention of MBD. Some of them are discussed below:
4.1 Physical activity
Individuals with MBD should be educated about the potential advantages of 
physical activity and motivated to be active within their ability and in keeping their 
values and goals as realistically possible. They should be given training on how to 
self-monitor for signs and symptoms that should be brought to their healthcare 
team’s attention and the emergency contact information for this team should be 
issued [16].
4.2 Adequate calcium and vitamin D intake
The Institute of Medicine (IOM) prescribes that dietary calcium consumption 
should be limited to 1000 mg daily for men aged 50–70 years, and 1200 mg daily for 
women aged 51 years and over [17]. Presently, the impact of calcium supplementa-
tion on stone formation is unclear. Large doses of supplemental calcium are likely to 
lead to stone formation, especially if given separately from a meal. If appropriate, 
patients with stones should be advised to take a meal with calcium supplements, 
and further, the disease condition needs to be closely monitored [18].
Vitamin D is a vital component of calcium absorption, which helps in the main-
tenance of bone health. The IOM recommends 600 IU and 800 IU per day for men 
and women who are aged 51–70 years and over 70 years, respectively [17]. Earlier 
reports indicate the fact that combined vitamin D and calcium intake demonstrated 
a reduction in the risk of fracture in older adults, but the effects varied according to 
the study setting, i.e., institution versus community dwellers. The risk of fracture 
among older adults was lower in the community dwellers than for institutionalized 
elderly people. However, further research is required for appropriate dose and dosing 
regimens to end up in a conclusive remark [19].
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4.3 Adequate protein intake
Maintaining an appropriate intake of proteins is vital for maintaining musculo-
skeletal functioning in postmenopausal women and men over the age of 50 years. 
The recommended protein intake is 0.8 g/kg/day [20].
4.4 Reducing the intake of caffeine
The impact of various caffeinated beverages has been inferred as a trigger of 
osteoporosis and fragility fracture in individuals; hence, it is recommended to 
restrict the intake of caffeine [21].
5. Treatment approaches for MBD
The recent decade has witnessed much progress in the introduction of new medi-
cations for the treatment of MBD. The treatment modality of this group of disorders 
comprises two major treatment regimens, antiresorptive and anabolic conventional 
therapies. Antiresorptive drugs predominantly reduce the bone resorption rate, while 
anabolic drugs boost the formation of bone. The following medicines for skeletal 
disorders, including Paget’s disease of the bone, osteoporosis, MBD, and several other 
rare type of bone diseases, form the basis of our current clinical treatment regimen.
5.1 Antiresorptive agents
The major class of drugs included in this category includes bisphosphonates, 
estrogens, calcitonin, and denosumab.
Bisphosphonates, first-line antiresorptive bone agents, are commonly used to 
treat osteoporosis caused by glucocorticoids and other disorders marked by severe 
osteoclastic bone resorption, such as humoral malignant hypercalcemia, Paget’s 
disease, multiple myeloma, and osteolytic bone metastasis [22]. The drugs specifi-
cally included in this group for the treatment of MBD comprises of alendronate, 
risedronate, and zoledronic acid. Such groups of therapeutic agents bind with a 
high affinity to the bone’s mineral matrix and prevent resorption of osteoclast of the 
bone, resulting in reduced bone turnover and a significant increase in bone mass 
[23]. The most prominent side effect related to bisphosphonates administered orally 
is the upper gastrointestinal discomfort, which majorly includes the erosion of the 
esophagus leading to ulcer, heartburn, and indigestion.
Calcitonin is approved for the treatment of osteoporosis care in postmenopausal 
women when alternative therapies are not practicable [24].
Denosumab, the first biological agent available for osteoporosis treatment, is a 
fully human monoclonal antibody that acts by inhibiting transmembrane protein 
(RANKL), which has proven results for the formation and functioning of osteo-
clasts, thereby reducing bone resorption. It is usually recommended for the patients 
who are unable to be on drug therapy, which are orally administered but are at high 
risk for the incidence of fractures. Denosumab is well-tolerated, but associated 
hypersensitivity or dermatological reactions, musculoskeletal pain, infections, 
and hypercholesterolemia are the major documented adverse effects. It can trigger 
hypocalcemia, so calcium levels should be fixed before starting treatment [25, 26].
5.2 Estrogen agonist/antagonist
Estrogen therapy is FDA approved exclusively for the prevention of osteopo-
rosis in postmenopausal women who are at high risk, and should only be used 
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when non-estrogenic osteoporotic medications have been deemed inappropriate. 
Hormonal replacement therapy is no longer recommended as a first choice for treat-
ing and preventing osteoporosis in postmenopausal and premenopausal women due 
to the overall associated health risks that hugely outweigh the benefits.
While antiresorptive drugs usually display a lower incidence of associated side 
effects, bone turnover suppression can elucidate the necrosis of the jaw and the 
incidence of atypical femur fractures that can be documented in patients with 
long-term bisphosphonate usage [27]. Because antiresorptive agents are unable to 
preserve bone mass and bone integrity, it continues to be of core interest to identify 
molecular targets that would promote osteoblast activity and lead to enhanced bone 
mass with reconstructed skeletal architectures.
5.3 Anabolic conventional therapies
Osteoanabolics are another category of drugs, which covers the PTH and 
parathyroid hormone-related peptide analogs. PTH functions as an efficient 
endocrine regulator for the maintenance of calcium and phosphate concentrations 
in extracellular space, vital to the preservation of concentration of calcium in serum 
and urinary samples within the normal physiological limit. High PTH levels lead 
to a high bone-turning state with bone resorption exceeding bone formation and 
ultimately osteoporosis precipitation [28].
Teriparatide was the first anabolic treatment option approved for the treatment 
of osteoporosis, which has a mode of action similar to that of the PTH hormone. 
This works by triggering the development of new bone by increasing osteoblastic 
development when given in low doses [29]. In patients with Paget’s bone disease, 
elevated concentrations of alkaline phosphatase, prior skeletal radiotherapy, 
recurrent or metastatic bone malignancy, hypercalcemic disorders such as primary 
hyperparathyroidism, avoidance of the treatment is suggested [30]. Abaloparatide 
is another FDA approved drug for the treatment of osteoporosis in postmenopausal 
women. It is further advised to avoid the treatment in patients with preexisting 
hypercalcemia and disorder such as primary hyperparathyroidism [31].
Another promising investigational drug is romosozumab, which is a sclerostin-
neutralizing antibody. Reports have shown elsewhere that it is better alternative 
bisphosphonate alendronate in women with severe osteoporosis for reducing the 
risk of prominent clinical fractures. This was accompanied by a boost in bone 
formation markers with a decline in bone resorption markers, implying the action 
of both stimulating bone formation and inhibiting bone resorption [32].
Apart from these two major classes of drugs, various herbal medicines are also 
gaining attention for being used in the treatment of MBD. Some of them include 
Hachimi-jio-gan and Juzen-taiho-to, Kami-kihi-to, Bushenningxin, Shu Di Shan 
Zha, and so on, which have proven reported results in various animal models on 
improving bone health [33, 34]. Reports suggest the fact that Hachimi-jio-gan and 
Juzen-taiho-to significantly prevented the loss of bone in SAMP6, a murine model 
for senile osteoporosis [34] The decoction containing Bushenningxin caused osteo-
blasts to have an increase in the number of cell organelles with clear Golgi apparatus, 
increased proliferation, and inhibition of apoptosis for a time period of 12 weeks 
when given to OVX mice [35].
Recent advances in MBD treatment include medications that target calcium-
sensing receptors and proteins linked to the hormone parathyroid, leading to the 
design of cathepsin K and Src tyrosine kinase inhibitors, calcilytics, and monoclo-
nal antibodies against sclerostin or Dickkopf-1 (Table 2).
Nanoenabled systems for the systemic delivery of drugs for the treatment of 
MBD have attracted huge attention in recent times. A number of formulations were 
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Class of drug Investigational 
drug
Characteristics Mode of action Therapeutic efficacy References
Calcilytics MK-5442 (Phase 
II)
Orally bioavailable CaSR antagonist Transient PTH pulses and a dramatic rise in the formation of bone 
markers were noted, with a transitory significant decline in markers 
of bone resorption. Compared to placebo, no further rise in BMD was 
reported
[36]
Cathepsin K 
inhibitors
ODN Long half-life, orally 
bioavailable
Inhibits CatK 
from binding to 
its corresponding 
substrates
Reduced bone turnover in ovariectomized animals and promoted 
periosteal bone formation was observed
[37]
ONO-5334 Synthetic derivative, 
low molecular weight, 
oral formulation
Inhibits CatK 
from binding to 
its corresponding 
substrates
In Phase 2 clinical trial in postmenopausal women with osteoporosis, 
there was a substantial enhancement in BMD in the lumbar spine, total 
hip, and femoral neck compared to placebo. The observed effect on BMD 
of ONO-5334 was found to have a similar effect as that of alendronate, 
when administered at a dose of 70 mg once weekly
[38]
Src tyrosine kinase 
inhibitors
Saracatinib 
(AZD0530)
Oral formulation Inhibits the 
enzyme Src kinase 
competitively
A notable decrease in bone resorption markers without any noticeable 
effect on bone formation markers and no serious adverse effects was 
documented, demonstrating a reduction in osteoclast bone resorption 
effect of saracatinib
[39]
Monoclonal 
antibodies against 
sclerostin/
Dickkopf-1
Romosozumab 
(AMG-785)
Human monoclonal 
anti-sclerostin antibody
Monoclonal antibody 
against sclerostin
A rise in dose-dependent BMD at the lumbar spine and total hip with a 
decrease in bone resorption markers with marked improvement in bone 
formation markers after a period of 3 months was reported
[40]
PTH, parathyroid hormone; CaSR, calcium sensing receptor; BMD, bone mineral density; CatK, cathepsin K.
Table 2. 
Recent advances for the treatment of metabolic bone disease.
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designed for the controlled delivery of medicaments for better therapeutic efficacy 
with minimal associated adverse effects. Some of the formulations reported in 
this specified category include tigecycline entrapped calcium phosphate/poly-DL-
lactide-co-glycolide nanoparticles, titanium implants coated with bisphosphonate 
encased calcium phosphate nanoparticle, and gold nanoparticles incorporated 
gelatin-based hydrogel. Reports suggest that surface reconfiguration through nano-
technology has played a significant role in the design and manufacture of better 
spinal implants [41–44].
6. Conclusion
The burgeoning of the incidences of MBD is raising concern worldwide. Proper 
screening of the disorder is of prime importance in dealing with it. Although 
bisphosphonates remain the first-line treatment choice for the stated disorder, 
researchers should work upon the novel drugs with a unique mode of action and 
appreciable long-term safety profile. Based on the literature, it is pertinent to 
state that a fine balance between the non-pharmacological and pharmacological 
approaches could help out in dealing with MBD judiciously resulting in its pre-
vention. Therefore, the battle for the search of better drugs for treating patients 
with metabolic bone diseases continues with an aim to provide better therapeutic 
efficacy and patient compliance.
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